Description

Simple

Clinical

Overview

Pharmacology

Indication

Investigated for use/treatment in epilepsy, huntington's disease, and parkinson's disease.

Pharmacodynamic

Information currently not available.

Mechanism of action

Information currently not available.

Absorption

Information currently not available.

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

Information currently not available.

Route of elimination

Information currently not available.

Toxicity

Information currently not available.

Adverse Effects

Contraindications

Information currently not available.

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Remacemide
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
(R)-warfarin
The serum concentration of (R)-warfarin can be increased when it is combined with Remacemide.
(S)-Warfarin
The serum concentration of (S)-Warfarin can be increased when it is combined with Remacemide.
2,5-Dimethoxy-4-ethylthioamphetamine
The risk or severity of adverse effects can be increased when Remacemide is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
3-isobutyl-1-methyl-7H-xanthine
Remacemide may increase the excretion rate of 3-isobutyl-1-methyl-7H-xanthine which could result in a lower serum level and potentially a reduction in efficacy.
4-Bromo-2,5-dimethoxyamphetamine
The risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Remacemide.
4-hydroxycoumarin
The metabolism of 4-hydroxycoumarin can be decreased when combined with Remacemide.
4-Methoxyamphetamine
The risk or severity of adverse effects can be increased when 4-Methoxyamphetamine is combined with Remacemide.
5-methoxy-N,N-dimethyltryptamine
The risk or severity of adverse effects can be increased when Remacemide is combined with 5-methoxy-N,N-dimethyltryptamine.
6-O-benzylguanine
Remacemide may increase the excretion rate of 6-O-benzylguanine which could result in a lower serum level and potentially a reduction in efficacy.
7-Deazaguanine
Remacemide may increase the excretion rate of 7-Deazaguanine which could result in a lower serum level and potentially a reduction in efficacy.
7-Nitroindazole
The risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Remacemide.
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline
The risk or severity of adverse effects can be increased when Remacemide is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.
7,9-Dimethylguanine
Remacemide may increase the excretion rate of 7,9-Dimethylguanine which could result in a lower serum level and potentially a reduction in efficacy.
8-azaguanine
Remacemide may increase the excretion rate of 8-azaguanine which could result in a lower serum level and potentially a reduction in efficacy.
8-chlorotheophylline
Remacemide may increase the excretion rate of 8-chlorotheophylline which could result in a lower serum level and potentially a reduction in efficacy.
9-aminocamptothecin
The metabolism of 9-aminocamptothecin can be decreased when combined with Remacemide.
9-Deazaguanine
Remacemide may increase the excretion rate of 9-Deazaguanine which could result in a lower serum level and potentially a reduction in efficacy.
9-Methylguanine
Remacemide may increase the excretion rate of 9-Methylguanine which could result in a lower serum level and potentially a reduction in efficacy.
Acefylline
Remacemide may increase the excretion rate of Acefylline which could result in a lower serum level and potentially a reduction in efficacy.
Acenocoumarol
The serum concentration of Acenocoumarol can be increased when it is combined with Remacemide.